25
Nov
2014
As you and your family review options for Medicare Part D prior to the Dec. 7, 2014 enrollment deadline, please consider coverage of any drugs related to Alzheimer's disease or other dementias.
Of particular note is a change to the availability of the Alzheimer's drug Namenda. The company that produces Namenda will cease production of one version of Namenda (Namenda IR tablets, usually taken twice per day) in January 2015.
While supplies of Namenda IR may be available at local pharmacies for a period of time after the company stops distribution in January, it is anticipated that individuals on this prescription will have to switch to another version of Namenda (XR = extended release once per day capsules). In addition, it is our understanding that a generic version of Namenda IR may be available as early as mid-2015; however, an official date has not been shared.
As with any prescription change, please have a conversation with your physician regarding options and next steps for you or your family members.
For more information regarding Medicare Part D, please visit our website.
Of particular note is a change to the availability of the Alzheimer's drug Namenda. The company that produces Namenda will cease production of one version of Namenda (Namenda IR tablets, usually taken twice per day) in January 2015.
While supplies of Namenda IR may be available at local pharmacies for a period of time after the company stops distribution in January, it is anticipated that individuals on this prescription will have to switch to another version of Namenda (XR = extended release once per day capsules). In addition, it is our understanding that a generic version of Namenda IR may be available as early as mid-2015; however, an official date has not been shared.
As with any prescription change, please have a conversation with your physician regarding options and next steps for you or your family members.
For more information regarding Medicare Part D, please visit our website.
